Champions Oncology
CSBR
16 hedge funds and large institutions have $13.1M invested in Champions Oncology in 2017 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 2 closing their positions.
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
45% more funds holding
Funds holding: 11 → 16 (+5)
20% more capital invested
Capital invested by funds: $10.9M → $13.1M (+$2.19M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.7% less ownership
Funds ownership: 39.4% → 37.7% (-1.7%)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SIM
Spark Investment Management
New York
|
+$141K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$93K |
| 3 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$58.3K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$19K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$14.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$636K |
| 2 |
Goldman Sachs
New York
|
-$127K |
| 3 |
SKK
Shepherd Kaplan Krochuk
Boston,
Massachusetts
|
-$110K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
-$39K |
| 5 |
PA
Perceptive Advisors
New York
|
-$19.7K |
CSBR Hedge Fund Activity: Q1 2017 in Review
16 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Champions Oncology (CSBR) for Q1 2017, worth a combined $13.1M — up 20% from $10.9M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new CSBR positions and 2 closed out — a net gain of 5 holders — while 2 added to existing stakes and 4 trimmed.
The largest buyer was Spark Investment Management, opening a new position worth an estimated $141K. The largest seller was Sabby Management, cutting an estimated $636K.
- 16 institutional investors held Champions Oncology (CSBR) as of Q1 2017, up from 11 in Q4 2016.
- Funds reported $13.1M of Champions Oncology stock for Q1 2017, up 20% quarter-over-quarter.
- 7 funds opened new Champions Oncology positions in Q1 2017 and 2 closed out, a net change of +5 holders.
- The largest Champions Oncology buyer in Q1 2017 was Spark Investment Management, an estimated $141K added.
- The largest Champions Oncology seller in Q1 2017 was Sabby Management, an estimated $636K sold.
Based on aggregated 13F filings for Q1 2017.